Postgraduate Medical School, Faculty of Health & Medical Sciences, University of Surrey, UK.
Future Oncol. 2011 Nov;7(11):1325-33. doi: 10.2217/fon.11.113.
Angiogenesis, one of the hallmarks of cancer, supplies nutrients to cancerous tissues to facilitate rapid growth. Targeting cancer-associated angiogenesis is an important goal in cancer therapy and there are currently many drugs that affect tumor-associated vasculature. In this article, we will focus on the antiangiogenic effects of zoledronate (ZA), a bisphosphonate drug routinely used in the treatment of cancer-associated bone disease. This article covers the known effects of ZA throughout the clinical process. It also covers the animal models of cancer that have been treated with ZA and evaluated for angiogenes is, concluding with the current clinical data pertaining to angiogenic factors after ZA treatment.
血管生成是癌症的特征之一，为癌变组织提供营养物质，促进其快速生长。针对与癌症相关的血管生成是癌症治疗的一个重要目标，目前有许多药物可以影响肿瘤相关的血管。在本文中，我们将重点介绍唑来膦酸（ZA）的抗血管生成作用，ZA 是一种双膦酸盐药物，常用于治疗与癌症相关的骨病。本文涵盖了 ZA 在整个临床过程中的已知作用。它还涵盖了用 ZA 治疗和评估血管生成的癌症动物模型，最后是关于 ZA 治疗后血管生成因子的当前临床数据。
